Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite.
Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination.
Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis.
Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia.
Neuromyelitis optica.
Amiloride HCl
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
Protective Associations of HDL with Blood Brain Barrier Injury in Multiple Sclerosis Patients.
Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases.
[Optical coherence tomography in multiple sclerosis].
High dose naltrexone for dyskinesias induced by levodopa.
Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.
Study Suggests Targeting B Cells May Help with MS
Santhera receives first product approval: Health Canada approves Catena® for treatment of Friedreich's ataxia
Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine.
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination.
Endogenous retroviruses and multiple sclerosis--new pieces to the puzzle.
Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients.
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.
Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features.
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.

Pages